Breakthrough - EUR 50 million investment for start-up BrainRepair
Pivotal trial on stem cell treatment for brain damage in newborns fully funded
Computer-generated image
BrainRepair UG has been granted the worldwide first ‘Orphan Drug Designations’ (ODD) by the European Commission / European Medicines Agency (EMA) and the Paediatric Investigation Plan (PIP) for the pivotal trial has been approved. The ODD guarantees market exclusivity in all EU member states for 12 years upon market authorisation.
“We are particularly grateful to Olaf Bolwerk, Johan Nijboer, and Dr. Alexander van der Speld who masterminded the transaction to fund our way towards market authorisation”, Prof. Dr. Arne Jensen stresses and continues, “All our personal, scientific, clinical, and philanthropic efforts serve the ultimate goal – to combat cerebral palsy, the most common disability in childhood – and stop CP in children!”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.